ALX Oncology (NASDAQ:ALXO) Shares Up 1%

ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Rating) shares traded up 1% during trading on Friday . The stock traded as high as $12.77 and last traded at $12.77. 45 shares were traded during mid-day trading, a decline of 100% from the average session volume of 179,238 shares. The stock had previously closed at $12.64.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Stifel Nicolaus reduced their price target on ALX Oncology from $35.00 to $16.00 in a report on Monday, June 6th. Credit Suisse Group reduced their price target on ALX Oncology from $43.00 to $38.00 and set an “outperform” rating for the company in a report on Tuesday, August 9th. Finally, Cantor Fitzgerald reduced their price objective on ALX Oncology from $60.00 to $32.00 in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.83.

ALX Oncology Stock Down 3.6 %

The firm has a fifty day moving average of $12.24 and a 200-day moving average of $12.37. The stock has a market capitalization of $496.34 million, a price-to-earnings ratio of -4.48 and a beta of 1.84.

Hedge Funds Weigh In On ALX Oncology

A number of institutional investors have recently made changes to their positions in ALXO. Legal & General Group Plc raised its holdings in shares of ALX Oncology by 40.6% in the second quarter. Legal & General Group Plc now owns 5,309 shares of the company’s stock worth $43,000 after acquiring an additional 1,534 shares during the last quarter. Amalgamated Bank acquired a new position in shares of ALX Oncology in the first quarter worth $49,000. American International Group Inc. raised its holdings in shares of ALX Oncology by 14.1% in the second quarter. American International Group Inc. now owns 10,040 shares of the company’s stock worth $81,000 after acquiring an additional 1,237 shares during the last quarter. Delphia USA Inc. acquired a new position in shares of ALX Oncology in the second quarter worth $82,000. Finally, Quantbot Technologies LP raised its holdings in shares of ALX Oncology by 61.3% in the second quarter. Quantbot Technologies LP now owns 11,453 shares of the company’s stock worth $92,000 after acquiring an additional 4,353 shares during the last quarter. 88.98% of the stock is owned by institutional investors and hedge funds.

About ALX Oncology

(Get Rating)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.

Read More

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.